EmeraMed Ltd is a biotechnology firm developing the lipophilic, blood-brain-barrier passing metal chelator and antioxidant Irminix® (Code: NBMI, INN: Emeramide). Mercury poisoning : The Company has Orphan Drug Designation for the Prevention and Treatment of Mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed. Phase 2b is in planning. COPD : A Phase 2a clinical trial is ongoing for the treatment of COPD and finished by November 2017.
| Website | http://www.emeramed.com |
| Revenue | $14 million |
| Funding | $3.6 million |
| Employees | View employees |
| Founded | 2007 |
| Address | 1648 McGrathiana Pkwy, Ste 310, Lexington, Kentucky 40511, US |
| Phone | +1 859-266-9200 |
| Industry | Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Pharmaceutical |
| Competitors | Medtronic, Boston Scientific, Abbott, Sysmex America, Inc., Philips, Siemens Healthineers, Bayer, Johnson & Johnson, Roche, FUJIFILM Business Innovation Asia Pacific +35 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541713 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular EmeraMed LTD employee's phone or email?
EmeraMed LTD Questions
The EmeraMed LTD annual revenue was $14 million in 2026.
EmeraMed LTD is based in Lexington, Kentucky.
The NAICS codes for EmeraMed LTD are [541713, 54, 54171, 541, 5417].
The SIC codes for EmeraMed LTD are [873, 87].
